Kornimate/medical-research-clean huggingface dataset:
chinese pd-snca registry

Conditions: Parkinson Disease

Summary: the purpose of the chinese pd-snca registry(cpd-sncar) is to develop a database of patients of parkinson's disease with a-synuclein (snca) gene variants in mainland china.

parkinson's disease (pd) is the second most common disorder among neurodegenerative diseases. snca is the first gene implicated in monogenic parkinsonism. however, some polymorphisms of snca gene such as rs894278 and rs11931074 can affect the risk of sporadic pd. the investigators aim to establish a database of pd with snca variants and characterize the clinical manifestation of these patients in mainland china. method: 1. peripheral blood from patients has been tested to have snca gene variants. 2. clinical manifestation will be measured by scales and neurological tests. standard scales include: unified parkinson's disease rating scale(updrs), hoehn-yahr stages, non-motor symptoms scale (nmss), mini-mental state examination (mmse), parkinson disease sleep scales (pdss), rapid eye movement sleep behaviour disorder questionnaire(rbdq-hk), epworth sleepiness scale (ess), rome iii functional constipation scale, the scale for outcomes in pd for autonomic symptoms (scopa-aut), parkinson fatigue scale (pfs), cambridge-hopkins restless legs syndrome questionnaire (chrlsq), hyposmia rating scale(hrs), hamilton depression scale, the 39-item parkinson's disease questionnaire(pdq-39), freezing of gait scale(fog), dyskinesia related scales, wearing-off scale(wo). 3. the investigators will also exam the blood biomarkers of pd such as uric acid and peripheral inflammatory markers.

Eligibility criteria:
inclusion criteria: * patients diagnosed with pd by the united kingdom parkinson's disease society brain bank clinical diagnostic criteria or other standard criteria; pd patients detected with positive snca variants exclusion criteria: -
virtual ileostomy versus conventional loop ileostomy

Conditions: Rectal Neoplasms

Summary: this study aimed at comparing the comprehensive complication index (cci), readmission rates, postoperative hospitalization days, duration of bearing the stoma (months), hospitalization costs, the number of hospitalizations with ghost ileostomy versus conventional loop ileostomy after low anterior resection for rectal cancer.

diverting ileostomy (di) is a common procedure performed in patients undergoing low anterior resection for rectal cancer to protect the anastomosis and reduce the risk of complications. although di remains one of the most common methods used in clinical practice to prevent anastomotic leakage, there is still considerable debate in clinical practice about whether to perform a routine ileostomy. despite temporary ileostomy fecal diversion can reduce the development of abdominal abscesses, wound inflammation, peritonitis, and sepsis after the occurrence of al, however, it not only failed to reduce the incidence of al but significantly increased the risk of non-elective readmissions and reinterventions as well as higher total costs. meanwhile, stoma significantly increase the risk of stoma-related complication such as small bowel obstruction, postoperative ileus, dehydration from high-output stoma culminating in acute kidney injury, electrolyte imbalance, stoma stenosis/ necrosis, parastomal hernia, peristomal abscess, and fistula, etc.

Eligibility criteria:
inclusion criteria: * pathologically confirmed low to intermediate level rectal cancer, with the lower margin of anastomosis \<10cm from the anus. * age ≥18 years and ≤80 years. * the surgical procedure is anterior rectal resection (lar). * intraoperative virtual or conventional ileostomy was performed. exclusion criteria: * bmi \>30 kg/m². * asa score \>3. * patients with coexisting complete intestinal obstruction. * history of long-term use of immunosuppressive drugs or glucocorticoids. * combined severe cardiac disease: with congestive heart failure or nyha cardiac function ≥ grade 2. patients with a history of myocardial infarction or coronary artery surgery within 6 months prior to the procedure. * chronic renal failure (requiring dialysis or glomerular filtration rate \<30 ml/min). intraoperative combined multi-organ resection. * combined cirrhosis of the liver. * intraoperative findings of incomplete anastomosis and positive insufflation test.

Keywords: virtual ileostomy diverting ileostomy rectal neoplasms rectosigmoid junction
effectiveness of gradual versus rapid weight loss

Conditions: Obesity

Summary: this randomized controlled trial aims to compare the 1-year effectiveness of an initial rapid weight loss (rwl) program and a gradual weight loss (gwl) program.

a total of at least 286 participants will be randomized to either a 16-week rapid weight loss (rwl) program; \[an 8-week low-energy-diet (\<1000 kcal/day) - followed by an 8-week gradual increase in energy intake (4 weeks \<1300 kcal/day and 4 weeks \<1500 kcal/day)\], or a 16-week gradual weight loss (gwl) program (controls); \[estimated total energy expenditure minus 800-1000 kcal/day\]. thereafter, all participants (both groups) will undergo a 36-week comprehensive weight maintenance program.

Eligibility criteria:
inclusion criteria: * • willing and able to give informed consent for participation in the study * living in the eastern part of norway, mainly oslo, buskerud, vestfold and akershus * understanding norwegian language written and spoken easily * bmi ≥30.0 kg/m2 * stable body weight (\<5 kg self-reported weight change) during the last 3 months before inclusion exclusion criteria: * • pregnancy and breast-feeding mothers * suspected non-compliance with regards to visits and/or diet * severe chronic disease (endocrine disease, heart disease, neurological disease, lung disease, disease in the gastrointestinal tract, kidney disease, rheumatism or cancer).
a retrospective chart review study of gene-eden-vir/novirin

Conditions: Herpes Simplex Infections; Human Papillomavirus; Epstein-Barr Virus Infections; Varicella-zoster Virus Infection; Cytomegalovirus Infections

Summary: this study measured the changes in health-related complaints by analyzing charts of individuals, who are infected with a latent virus, who have used gene-eden-vir/novirin.

the medical community calls the movement from severe to mild disease and from mild to normal health, 'relieving symptoms', and the interventions that cause such movement, drugs, medications, or therapies. the alternative community calls the movement from normal health to superior health, 'boosting health' (or boosting the immune system, or improving your sex drive, or boosting any another well functioning physiological system), and the interventions that cause such movement, natural remedies, dietary supplements, complementary treatments, etc. in general, these interventions aim to achieve superior performance of a normal human body. of course, boosting the body's normal performance improves many of its capabilities, such as higher resistance to diseases, faster recovery from fatigue, better mental concentration, etc. each movement presents different objectives. relieving symptoms represents the ability of an intervention to reduce the frequency, duration, and severity of a disease. in contrast, boosting health represents the ability of an intervention to increase the frequency, duration, and quality of a person's health. in the current study, the investigators would like to measure the changes in health-related complaints by analyzing charts of individuals, who are infected with latent virus, and who have used gene-eden-vir/novirin.

Eligibility criteria:
inclusion criteria: * latent viral infection with either hsv, hpv, vzv, ebv, or cmv * taking gene-eden-vir/novirin exclusion criteria: * use of other antiviral treatments
x-ray dose reduction in electrophysiology

Conditions: Arrhythmias, Cardiac

Summary: allura clarity is a novel x-ray imaging technology, that combines advanced real-time image noise reduction algorithms, with state-of-the-art hardware to reduce patient entrance dose significantly. this is realized by anatomy-specific optimization of the full acquisition chain (grid switch, beam filtering, pulse width, spot size, detector and image processing engine) for every clinical task individually. furthermore, smaller focal spot sizes and shorter pulses are used, which are known to positively influence image quality . the primary aim of this study is to verify if a significant reduction in total procedural x-ray dose during electrophysiological interventions can be achieved by using advanced image processing (allura clarity).

x-ray dose and image quality are related by laws of physics. low dose and high image quality cannot be achieved at the same time. however, image processing algorithms can help an x-ray system to acquire images with lower dose without influencing image quality or achieving higher image quality with equal dose. in order to introduce a dose reduction technology the most important aspect is to validate the diagnostic image information. philips has developed a new algorithm that is capable to process images with similar image quality but acquired at lower dose.

Eligibility criteria:
inclusion criteria: * patients with heart rhythm disturbances undergoing an interventional treatment for their heart rhythm disturbance * patients who are allowed, able, willing to and have provided informed consent * patients to be treated with ablation for atrial fibrillation (paroxysmal, persistent or permanent), atypical atrial flutter or patients to be treated with ablation for ischemic or non-ischemic ventricular tachycardia * patients who are treated in heart catheterization room 5 (hck5) of the catherina hospital exclusion criteria: * patients under 18 years of age. * patient who are pregnant or breast feeding.

Keywords: x-rays cardiac electrophysiology image processing, computer-assisted catheter ablation
qlaris study of qls-111 in combination with a pga for oag and/or oht patients

Conditions: Open-angle Glaucoma (OAG); Ocular Hypertension (OHT); Glaucoma

Summary: qlaris phase 2 clinical study investigating the safety, tolerability, and ocular hypotensive efficacy of qls-111 in combination with latanoprost in open-angle glaucoma (oag) and/or ocular hypertension (oht) patients.

pilot, double-masked, vehicle-controlled, randomized, prospective parallel study of 14-day once daily evening (qpm) dosing, followed by 14-day twice daily (bid) dosing of an investigational product (ip), qls-111, or vehicle as concomitant therapy with monotherapy latanoprost a pga treatment that is administered qpm. both eyes (ou) will be dosed. the study is comprised of seven (7) visits and approximately 28 days of ip dosing.

Eligibility criteria:
inclusion criteria: * 12 years or older * able and willing provide signed informed consent (assent) * mild to moderate oag or oht in at least one eye and current or previous treatment with pga. exhibits decrease (i.e., \>20% from reported pre- treatment) in intraocular pressure (iop). patient is willing to continue latanoprost throughout the study. * iop ≥19 mmhg at 08:00 hour (h) at qualification visits prior to randomization exclusion criteria: * history of active ocular disease other than mild to moderate oag/oht * nonresponse to and/or noncompliant with pga treatment * use of other topical ocular medications with exception of the pga which the patient will use throughout the study * moderate to severe glaucomatous damage in either eye * previous glaucoma intraocular surgery in either eye (e.g., trabeculectomy, tubes, cyclodestructive procedures, diode) with exception of selective laser trabeculoplasty (slt) if done less than 12 months from screening, trabecular meshwork minimally invasive glaucoma surgery (migs) when combined with cataract surgery and done less than 12 months from screening. * significant ocular trauma, or intraocular surgery (e.g., cataract extraction/intraocular lens insertion) or extensive retinal laser treatment, refractive surgery in either eye. * ocular infection, inflammation (e.g., uveitis), moderate to severe blepharitis/meibomitis and/or severe keratoconjunctivitis sicca in either eye at screening, history of herpes simplex keratitis, in either eye. * clinically significant retinal disease in either eye * clinically significant systemic or psychiatric disease * participation in any investigational study within 30 days prior to screening * pregnant or lactating

Keywords: qlaris oag glaucoma pga therapy apteryx i oht latanoprost
effects of attentional focus strategy on dual-task walking training in patients with parkinson's disease

Conditions: Parkinson Disease; Dual-task Walking

Summary: walking deficits and altered brain capacity have been proved to be two of the main contributing factors in dual-task walking deficits in patients with parkinson's disease (pd). in the past, patients with pd were usually suggested not to walk in dual-task conditions in order to concentrate on their walking performance better. however, since dual-task walking is really common in daily-life, this limitation usually lead to a decrease in quality of life for pd patients. in previous studies, effects of using attentional strategies in dual-task walking training remain unclear, while suitable attentional strategies and corresponded neuroplasticity for patients with and without freezing of gait have not been well discussed, either. accordingly, this study is aimed to identify (1) whether internal or external attentional strategies is more ideal for pd patients with and without freezing of gait in dual-task walking training, and (2) changes in brain activity after receiving dual-task walking training with different attentional strategies in patients with or without freezing of gait. our hypothesis are (1) patients with or without freezing of gait will react differently in dual-gait training with different attentional strategies, and (2) changes in brain activities will be different according to different attentional strategies given in the training.

the hypothesis will be tested by gait performance, suprapostural tasks performance, relative power spectrum of eeg, and scales including mds-updrs, abc, bbs, and tug.

Eligibility criteria:
inclusion criteria: for pd patients: * (1) a diagnosis of idiopathic pd by a neurologist expert in movement disorders (2) onset age \> 40 years old, (3) presence of gait disorders or freezing of gait (points on 3.10 in mds-updrs\>=1 or points on item 3 in nfog-q \>0) (4) able to walk independently without an assistance device at least for 20 meters (5) without obvious action or postural tremor, according to the score of 3.15 and 3.16 (action and postural tremor of hands) in mds-updrs for healthy elders: * (1) without musculoskeletal of neurological diseases which may affect balance or walking performance (2) no medication that might influence their balance or cognition (3) mmse\> 26 points. exclusion criteria: for pd patients: * (1) with other neurological or musculoskeletal disease that might affect balance or walking (2) have a mini-mental state examination (mmse) \< 27 points (3) have a history of brain surgery (4) have to modulate their medication for duration of the experiment.

Keywords: parkinson dual-task training attention electroencephalogram (eeg)
family engagement, cross-system linkage to substance use treatment for juvenile probationers -- phase 3

Conditions: Substance Use; Substance Abuse; Substance Use Disorders; Substance-Related Disorders; Substance Dependence; Substance Related Problem

Summary: developed from adapting and combining two evidence-based programs, project connect (a linkage-to-services program that targets barriers within the probation and substance abuse treatment systems) and ties (a program that teaches family engagement skills to providers), family connect is a linkage-to-services program that targets both family and system-level factors to increase youth use of and retention in substance use services. using linkage specialists embedded within probation departments, family connect will be implemented in two nys probation departments. this proposed study will evaluate the impact of family connect on (1) youth referral from probation to substance abuse treatment, (2) youth and family engagement in substance abuse treatment, (3) youth enrollment/retention in substance abuse treatment, and (4) youth substance use and recidivism. counts of youth referred, youth who start treatment, and youth retained in treatment will be obtained from the juvenile justice agency for 6-months pre-implementation of family connect (i.e. baseline) and during the implementation period of e-connect; counts of youth recidivism will be obtained 6 months following the completion of family connect. this study will also identify family and probation organizational factors influencing family connect implementation in probation settings. 50 caregiver-youth dyads and up to 36 probation officers will be recruited as participants in the study. caregiver-youth dyads will be evaluated at baseline, 2 and 6 months; probation officers at baseline, 6, 12, and 18 months; linkage specialists at baseline, 6, 12, and 18 months.


Eligibility criteria:
youth: inclusion criteria 1. between 10-18 years of age 2. english speaking 3. a caregiver who will participate in the study 4. maysi-2 score of ≥ 4 on any maysi-2 subscale; yasi mental health and substance use screen items; or other documented evidence of mental health or substance use problem 5. currently on probation exclusion criteria 1. cognitively unable to complete the interview caregiver: inclusion criteria 1. youth's legal guardian (or permission from legal guardian) 2. youth who will participate 3. english speaking exclusion criteria: 1. cognitively unable to complete the interview probation staff: inclusion criteria: 1. currently employed at probation department exclusion criterion: 1. none

Keywords: drug use drug addiction drug habituation drug use disorders organic mental disorders substance-induced substance abuse substance addiction substance dependence substance use disorders
accuracy of photogrammetric three-dimensional facial models reconstruction compared with direct anthropometry

Conditions: Dental Malocclusion; Diagnosis; Facial Asymmetry

Summary: accuracy of two different photogrammetric software for three dimensional facial model reconstructions compared with direct facial anthropometry.


Eligibility criteria:
inclusion criteria: * participants aged 18 or older exclusion criteria: * presence of: 1. extensive facial hair (beards). 2. significant facial defects. 3. surgical scars. 4. neuromuscular disorders that may hinder stability of head during image acquisition. 5. accessories that could interfere with image acquisition.

Keywords: facial scanning photogrammetry facial anthropometry
anesthesia standard operating procedure during on-pump coronary artery bypass grafting

Conditions: Coronary Artery Disease; Low Cardiac Output Syndrome; Atrial Fibrillation; Postoperative Complications

Summary: background: despite improvements in surgical and anesthesia procedures over the past 15 years complications during cardiac surgery still remain high. bridgewater b et al. describes mortality during on-pump coronary artery bypass grafting (cabg) at 2%-3%, and the rate postoperative complications about 20%-30%. at the same time, the standard of care in patients undergoingon-pump cabg is not fully established. hypothesis, research need: use of multimodal low-dose opioid anesthesia during cabg decreases inflammatory response and the incidence of early postoperative cardiac complications due to a reduction in interleukin-6. methodology: according to anesthesia standard protocol, all patients were divided into two groups - study group with multimodal low-dose opioid anesthesia (60 patients) and control group with a high-dose opioid anesthesia (60 patients). primary (il-6 at the end of the operation) and secondary clinical outcomes (postoperative atrial fibrillation (poaf), low cardiac output syndrome (lcos), duration of mechanical ventilation (mv), length of intensive care unit (icu) stay, length of hospital stay) were compared between the groups. analysis tools: clinical observations; instrumental research methods (electrocapdiography, echocardiography); labs (blood gases, hemoglobin, electrolytes); enzyme-linked immunosorbent assay (il-6); statistical (student's t-test, mann-whitney u test, χ2-test, correlation analysis). expected outcomes: use of multimodal low-dose opioid anesthesia during cabg will decrease inflammatory response (lower levels of il-6 at the end of the surgery) and the incidence of early postoperative cardiac complications, expressed as lower incidence of lcos and poaf, lower duration of mv and lower length of icu stay.


Eligibility criteria:
inclusion criteria: * age from 44 to 65 years, * nn ejection fraction \> 30%, * operational risk assessment for euroscore ii \<5%, * on-pump coronary artery bypass grafting exclusion criteria: * patient's refusal * off-pump coronary artery bypass grafting * the need for additional intervention on the heart

Keywords: coronary artery bypass grafting cardiopulmonary bypass coronary artery disease low cardiac output syndrome low-dose opioid anesthesia postoperarive atrial fibrillation il-6
optimisation of the treatment of infectious bursitis

Conditions: Olecranon Bursitis; Patellar Bursitis

Summary: the study investigates prospectively the cost-savings related to a one-stage bursectomy (debridement, drainage and closure at the same time) versus two-stage bursectomy (debridement, left open and closure at a second time) of severe bursitis among hospitalized patients for surgical treatment of septic bursitis. we suppose that the one-stage bursectomy reveals similar recurrence rates but is associated with a significant shortening of hospital stay, consumption of resources and increased patient satisfaction.

start as single center interventional study at geneva university hospitals study open for additional centres (electronic crf) funding on 24.6.2011 (50,000 swiss francs). further demand for funding ongoing. septic bursitis of knee and elbows, for which the patients are hospitalised (a substantial part of patient with failure of conservative treatment) randomisation 1:1 (one-stage vs. two-stage). duration of concomitant postsurgical antibiotic therapy fixed to 7 days exclusion of severely immuno-depressed patients. assessment of all costs of inpatient treatment and outpatient follow-up of included cases. interim analysis after ca. 100 cases planified.

Eligibility criteria:
inclusion criteria: 1. age \>18 years 2. hospitalized for bursectomy for septic bursitis exclusion criteria: 1. bacteraemic diseases 2. presence of another concomitant infection requiring antibiotics 3. presence of osteosynthesis material beneath the bursitis 4. septic bursitis outside of the elbow or the knee 5. severe immune suppression (transplantation, hiv with cluster of differentiation cell count \<200 cells/mm3, immune suppressive treatment with equivalence of more than 15 mg of prednisone daily ). 6. recurrent septic bursitis episodes

Keywords: septic bursitis bursectomy primary closure
clinical analysis of ocular parameters contributing to intraoperative pain during standard phacoemulsification

Conditions: Phacoemulsification

Summary: charts of 142 patients who underwent standard phacoemulsification under topical anesthesia between march and august 2016 were reviewed. the pain during phacoemulsification and 1 h after surgery was assessed and compared using a visual analog scale.

patients scheduled for elective phacoemulsification and intraocular lens implantation with the infiniti vision system (alcon, fort worth, usa) were included. all operations were performed in kyungpook national university hospital by the same surgeon between march and august 2016.

Eligibility criteria:
inclusion criteria: * patients underwent phacoemulsification with topical anesthesia exclusion criteria: * patients who needed general anesthesia or were taking medications capable of affecting perceived pain * patients who had traumatic cataract and/or conditions likely to require vitrectomy and trans-scleral fixation of posterior chamber intraocular lens

Keywords: pain axial length anterior chamber depth intraocular pressure